At Ayala, we are dedicated to developing targeted therapies specifically for patients living with rare and aggressive diseases. In combination with next-generation sequencing and our proprietary bioinformatics platform, we are pioneering a novel approach to cancer treatment.
March 03, 2023
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
February 10, 2023
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022